News - MedImmune

Filter

Current filters:

MedImmune

Popular Filters

Heptares meets milestone in MedImmune research collaboration

Heptares meets milestone in MedImmune research collaboration

23-01-2014

UK-based drug company Heptares Therapeutics has successfully completed the research phase of its antibody…

AstraZenecaBiotechnologyHeptares TherapeuticsMedImmuneResearchUK

AstraZeneca in deal with Immunocore to develop novel cancer therapies

AstraZeneca in deal with Immunocore to develop novel cancer therapies

08-01-2014

UK privately-held biotech firm Immunocore has signed an oncology research collaboration and licensing…

AstraZenecaBiotechnologyImmunocoreLicensingMedImmuneOncologyResearch

Immunologist Yong-Jun Liu named head of research at MedImmune

Immunologist Yong-Jun Liu named head of research at MedImmune

20-11-2013

US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca…

BoardroomImmunologicalsMedImmuneNorth AmericaPharmaceuticalUSA

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

15-10-2013

AstraZeneca revealed this morning that its biologics subsidiary MedImmune has acquired Spirogen, a privately-held…

ADC TherapeuticsAstraZenecaMedImmuneMergers & AcquisitionsOncologyPharmaceuticalSpirogen

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

AstraZeneca plans to move three cancer drug candidates into Ph III

16-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning (May 16) announced that it will be moving…

AstraZenecaBiotechnologyMedImmunemoxetumomab pasudotoxolaparibOncologyPharmaceuticalResearchselumetinib

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

iBio uses iBioLaunch technology to produce functional MAb copy of Synagis

11-04-2012

US biotech firm iBio (NYSE AMEX: IBIO) says that its proprietary iBioLaunch technology for the production…

AstraZenecaBiotechnologyiBIOMedImmunePalivizumabResearchRespiratory and PulmonarySynagis

Further $100 million committed to AstraZeneca’s MedImmune Ventures

29-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed yesterday that it has committed an additional…

AstraZenecaFinancialMedImmuneMergers & AcquisitionsPharmaceutical

AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy

02-11-2011

USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics…

AgonOxAstraZenecaBiotechnologyLicensingMedImmuneOncologyPharmaceuticalResearch

AstraZeneca unit in-licenses Pfizer drug candidate tremelimumab

04-10-2011

Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) US biologics subsidiary MedImmune has in-licensed…

AstraZenecaLicensingMedImmuneOncologyPfizerPharmaceutical

UK Judge denies AstraZeneca/MedImmune patent rights

07-07-2011

The High Court this week ruled that Anglo-Swedish drug major AstraZeneca (LSE: AZN) subsidiary MedImmune’s…

AstraZenecaBiotechnologyEuropeLucentisMedImmuneNovartisOphthalmicsPatentsPharmaceuticalRoche

Company Spotlight

Fibrotech

Fibrotech

Back to top